| Steven F Will, MD | |
|
20 Myers Farm Rd, Hingham, MA 02043-3182 | |
| (781) 749-5369 | |
| Not Available |
| Full Name | Steven F Will |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 20 Myers Farm Rd, Hingham, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083686067 | NPI | - | NPPES |
| 1083686067 | Medicaid | IA | |
| 469629 | Other | IA | COVENTRY HEALTH CARE OF IA |
| 1083686067 | Other | IA | WELLMARK BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 207947 (Massachusetts) | Secondary |
| 207T00000X | Neurological Surgery | 0101239924 (Virginia) | Primary |
| Entity Name | Berkshire Faculty Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548212939 PECOS PAC ID: 8224068424 Enrollment ID: O20050817001122 |
News Archive
Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
Pharmacyclics, Inc. today announced that it has increased the number of shares to be sold in the registered direct offering previously announced on June 15, 2010 by approximately 1.9 million shares, for a total offering of approximately 8 million shares. The increase in the number of shares was due to additional demand from institutional investors who were previously participating in the registered direct offering.
Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven F Will, MD 20 Myers Farm Rd, Hingham, MA 02043-3182 Ph: (781) 749-5369 | Steven F Will, MD 20 Myers Farm Rd, Hingham, MA 02043-3182 Ph: (781) 749-5369 |
News Archive
Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
Pharmacyclics, Inc. today announced that it has increased the number of shares to be sold in the registered direct offering previously announced on June 15, 2010 by approximately 1.9 million shares, for a total offering of approximately 8 million shares. The increase in the number of shares was due to additional demand from institutional investors who were previously participating in the registered direct offering.
Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.
› Verified 3 days ago